Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSplitomicin is a inhibitor of Sir2p (IC50 = 60 μM), an NAD+-dependent Sir2 family deacetylase required for chromatin-dependent silencing in yeast.
分子量 | 198.22 |
公式 | C13H10O2 |
储存 | Store at -20°C |
纯度 | ≥97% (HPLC) |
CAS Number | 5690-03-9 |
PubChem ID | 5269 |
InChI Key | ISFPDBUKMJDAJH-UHFFFAOYSA-N |
Smiles | O=C1CCC2=C(O1)C=CC1=CC=CC=C21 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Bedalov et al (2001) Identification of a small molecule inhibitor of Sir2p. Proc.Natl.Acad.Sci.U.S.A. 98 15113 PMID: 11752457
关键词: Splitomicin, Splitomicin supplier, Sir2p, inhibitors, inhibits, Sirtuin, Sir2-like, Family, Deacetylases, Class, III, HDACs, (Sirtuins), 1542, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 Splitomicin 的部分引用包括:
Kumari and Usdin (2014) Polycomb group complexes are recruited to reactivated FMR1 alleles in Fragile X syndrome in response to FMR1 transcription. Hum Mol Genet 23 6575 PMID: 25055869
Stavrou et al (2015) Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. J Neurosci 125 710 PMID: 25339356
目前没有该产品的评论。 Be the first to review Splitomicin and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.